Rydex Biotechnology Adv
9601 Blackwell Road Suite 500 Rockville MD 20850
Map
Phone: 800-820-0888
| Category: | Specialty-Health | | Fund Family: | Rydex | | Net Assets: | 8.19M | | Year-to-Date Return: | -10.84% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 01-Apr-98 |
|
Michael P. Byrum
Lead Manager since
01-Apr-98 | | | Byrum is president and CIO of Rydex Investments. He has ultimate responsibility for the management of the Funds. He has been associated with Rydex Investments since it was founded in 1993. He was was named the president of Rydex Investments in 2004 and has served as Chief Investment Officer of Rydex Investments since 2003. Ryrum holds the Charted Financial Analyst designation. |
| Min Initial Investment: | $2,500 | | Min Initial Investment, IRA: | $1,000 | | Min Initial Investment, AIP: | $0 | | Min Subsequent Investment: | $0 | | Min Subsequent Investment, IRA: | $0 | | Min Subsequent Investment, AIP: | $0 |
|
| |
| The investment seeks capital appreciation. The fund primarily invests in equity securities issued by biotechnology companies that are traded in the United States, as well as in futures and options contracts. Biotechnology companies include those engaged in the research, development, and manufacture of various biotechnological and biomedical products. It is nondiversified. |
| Last Dividend
| N/A | | Last Cap Gain
(10-Nov-99):
| 0.04 | | Annual Holdings Turnover
| 193.00% | | Average for Category:
| 109.57% |
|
| Expense | RYOAX | Category
Avg | | Total Expense Ratio: | 1.89%
| 1.66% | | Max 12b1 Fee: | 0.25%
| N/A | | Max Front End Sales Load: | 0.00%
| 5.32% | | Max Deferred Sales Load: | 0.00%
| 2.96% | | 3 Yr Expense Projection*: |
$594 | $720 | | 5 Yr Expense Projection*: |
$1,021 | $1,068 | | 10 Yr Expense Projection*: |
$2,212 | $2,074 |
|
|
2.63% Nasdaq 0.00%
Profile
